Schonfeld Strategic Advisors LLC Has $352,000 Stock Holdings in Rezolute, Inc. (NASDAQ:RZLT)

Schonfeld Strategic Advisors LLC trimmed its position in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 79.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 71,932 shares of the company's stock after selling 272,368 shares during the quarter. Schonfeld Strategic Advisors LLC owned approximately 0.12% of Rezolute worth $352,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. JPMorgan Chase & Co. bought a new position in Rezolute during the third quarter valued at approximately $42,000. Alpine Global Management LLC acquired a new position in shares of Rezolute during the 4th quarter worth $54,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Rezolute by 65.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock valued at $112,000 after purchasing an additional 9,000 shares in the last quarter. Oxford Asset Management LLP bought a new position in shares of Rezolute during the 4th quarter valued at $154,000. Finally, ExodusPoint Capital Management LP acquired a new stake in shares of Rezolute in the 4th quarter valued at $277,000. Institutional investors own 82.97% of the company's stock.

Rezolute Stock Up 1.8%

RZLT stock traded up $0.07 during mid-day trading on Friday, reaching $3.63. 251,495 shares of the stock traded hands, compared to its average volume of 623,131. The firm has a market capitalization of $219.44 million, a PE ratio of -2.97 and a beta of 1.01. The business has a 50-day moving average of $3.24 and a two-hundred day moving average of $4.32. Rezolute, Inc. has a 52 week low of $2.22 and a 52 week high of $6.19.

Rezolute (NASDAQ:RZLT - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05). On average, equities research analysts anticipate that Rezolute, Inc. will post -0.93 EPS for the current fiscal year.

Analysts Set New Price Targets

RZLT has been the subject of a number of recent research reports. Guggenheim reiterated a "buy" rating on shares of Rezolute in a report on Monday, February 10th. Craig Hallum upgraded Rezolute to a "strong-buy" rating in a research note on Tuesday, February 4th. HC Wainwright reissued a "buy" rating and set a $14.00 price objective on shares of Rezolute in a report on Monday, April 28th. Wedbush restated an "outperform" rating and issued a $12.00 target price on shares of Rezolute in a report on Wednesday. Finally, JMP Securities upped their target price on Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a research report on Thursday, February 13th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $12.14.

Insiders Place Their Bets

In related news, Director Wladimir Hogenhuis acquired 10,000 shares of the stock in a transaction dated Tuesday, February 18th. The shares were acquired at an average price of $4.70 per share, for a total transaction of $47,000.00. Following the completion of the purchase, the director now owns 77,267 shares in the company, valued at approximately $363,154.90. The trade was a 14.87% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Nevan C. Elam acquired 12,302 shares of the stock in a transaction dated Thursday, March 27th. The stock was bought at an average price of $2.85 per share, for a total transaction of $35,060.70. Following the purchase, the chief executive officer now owns 224,119 shares of the company's stock, valued at $638,739.15. The trade was a 5.81% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 39,060 shares of company stock valued at $130,694 in the last three months. Company insiders own 18.39% of the company's stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.